Novartis pays big premium to get hands on AveXis in $8.7 billion deal
ZURICH (Reuters) – Novartis plans to buy AveXis for $218 per share in a $8.7 billion cash deal, adding a therapy hopeful for spinal muscular atrophy (SMA) to the Swiss drugmaker’s pipeline that is expected to reap...
Read More